MMC Laboratories Limited has announced the development of a pharmaceutical-grade cannabis processing facility in Lilongwe, projected to generate up to USD 300 million in annual export revenue for Malawi within the next two to four years.

The announcement was made during the groundbreaking ceremony held at Mbabzi Estate, where representatives from government, development finance institutions, and the private sector gathered to launch the multi-stakeholder initiative. The USD 10 million project is a partnership between MMC Laboratories, the Export Development Fund (EDF), Mbabzi Estate, and the Malawi Agricultural and Industrial Investment Corporation (MAIIC).

The facility will comply with EU Good Manufacturing Practice (GMP) standards and support the production and export of high-value cannabis-derived Active Pharmaceutical Ingredients (APIs), including cannabis flos, CBD oils, terpenes, and purified rare cannabinoids.